Anticancer research · 2026
Stereotactic Body Radiation Therapy for Spinal Metastasis Using Biaxially Rotational Dynamic Radiation Therapy (BROAD-RT).
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ueta Akira, Aizawa Rihito, Ono Yuka, Iizuka Yusuke, Nakamura Kiyonao, Mukumoto Nobutaka, Hirashima Hideaki, Nakamura Mitsuhiro, Mizowaki Takashi
Аннотация
BACKGROUND/AIM: This study aimed to report clinical outcomes of spine stereotactic body radiation therapy (SBRT) using biaxially rotational dynamic radiation therapy (BROAD-RT), which is a novel non-coplanar volumetric-modulated arc therapy (VMAT) technique that does not require couch rotation or patient repositioning.
PATIENTS AND METHODS: We retrospectively analyzed 13 patients who received spine SBRT using BROAD-RT in a prospective feasibility study conducted between August 2020 and April 2022. The prescribed dose was 27 Gy in 3 fractions. Patient-specific dosimetric quality assurance (QA) using ArcCHECK was conducted.
RESULTS: The median age of patients was 73 years old. Primary cancers involved the prostate (23.0%, N=3), lung (15.4%, N=2), breast (15.4%, N=2), liver (15.4%, N=2), thyroid (15.4%, N=2), malignant meningioma (7.7%, N=1), and synovial sarcoma (7.7%, N=1). Overall, 84.6% of patients (N=11) had oligo-metastatic disease at the time of SBRT. QA showed average (±standard deviation) passing rates of 96.4 ± 2.5%. The median follow-up period was 36.2 months. Local control (LC) and overall survival (OS) rates were 84.6 and 100% at one year, and 59.8 and 68.4% at three years, respectively. The cumulative incidence of grade ≥2 vertebral compression fracture (VCF) was 7.7 and 23.1% at one and three years, respectively. Other than VCF, no grade ≥3 toxicities or radiation-induced myelopathies were observed.
CONCLUSION: BROAD-RT enabled the easy application of non-coplanar VMAT in spine SBRT with marked accuracy. Treatment with 27 Gy in three fractions resulted in acceptable toxicity, although LC was relatively low. These findings highlight both the feasibility of BROAD-RT and the need for further investigation of dose and fractionation strategies.
PATIENTS AND METHODS: We retrospectively analyzed 13 patients who received spine SBRT using BROAD-RT in a prospective feasibility study conducted between August 2020 and April 2022. The prescribed dose was 27 Gy in 3 fractions. Patient-specific dosimetric quality assurance (QA) using ArcCHECK was conducted.
RESULTS: The median age of patients was 73 years old. Primary cancers involved the prostate (23.0%, N=3), lung (15.4%, N=2), breast (15.4%, N=2), liver (15.4%, N=2), thyroid (15.4%, N=2), malignant meningioma (7.7%, N=1), and synovial sarcoma (7.7%, N=1). Overall, 84.6% of patients (N=11) had oligo-metastatic disease at the time of SBRT. QA showed average (±standard deviation) passing rates of 96.4 ± 2.5%. The median follow-up period was 36.2 months. Local control (LC) and overall survival (OS) rates were 84.6 and 100% at one year, and 59.8 and 68.4% at three years, respectively. The cumulative incidence of grade ≥2 vertebral compression fracture (VCF) was 7.7 and 23.1% at one and three years, respectively. Other than VCF, no grade ≥3 toxicities or radiation-induced myelopathies were observed.
CONCLUSION: BROAD-RT enabled the easy application of non-coplanar VMAT in spine SBRT with marked accuracy. Treatment with 27 Gy in three fractions resulted in acceptable toxicity, although LC was relatively low. These findings highlight both the feasibility of BROAD-RT and the need for further investigation of dose and fractionation strategies.